EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to alpha-cyclodextrin and reduction of post-prandial glycaemic responses (ID 2926, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to alpha-cyclodextrin and reduction of post-
prandial glycaemic responses (ID 2926, further assessment) pursuant to Article 13(1)
of Regulation (EC) No 1924/2006
EFSA publication; Tetens, Inge
Link to article, DOI:
10.2903/j.efsa.2012.2713
Publication date:
2012
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA publication (2012). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to alpha-cyclodextrin and reduction of post-prandial glycaemic
responses (ID 2926, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Parma,
Italy: European Food Safety Authority.  (The EFSA Journal; No. 2713, Vol. 10(06)). DOI:
10.2903/j.efsa.2012.2713
  EFSA Journal 2012;10(6):2713 
 
Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the 
substantiation of health claims related to alpha-cyclodextrin and reduction of post-prandial glycaemic responses (ID 2926, 
further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10(6):2713 [17 pp.]. 
doi:10.2903/j.efsa.2012.2713. Available online: www.efsa.europa.eu/efsajournal  
 
1 © European Food Safety Authority, 2012 
SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
alpha-cyclodextrin and reduction of post-prandial glycaemic responses 
(ID 2926, further assessment) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to provide a scientific opinion on a health claim pursuant to Article 13.1 of Regulation (EC) No 1924/2006 
in the framework of further assessment related to alpha-cyclodextrin and reduction of post-prandial glycaemic 
responses. The food constituent that is the subject of the claim, alpha-cyclodextrin, is sufficiently characterised. 
The claimed effect, reduction of post-prandial glycaemic responses (as long as post-prandial insulinaemic 
responses are not disproportionally increased), may be a beneficial physiological effect. The proposed target 
population is individuals who wish to reduce their post-prandial glycaemic responses. In weighing the evidence, 
the Panel took into account that two intervention studies showed a significant effect of alpha-cyclodextrin added 
to starch on post-prandial glycaemic responses without disproportionally increasing post-prandial insulinaemic 
responses, that one study on alpha-cyclodextrin added to sucrose did not show an effect on post-prandial 
glycaemic responses, and that there is some evidence in support of a plausible mechanism by which alpha-
cyclodextrin could exert the claimed effect. On the basis of the data presented, the Panel concludes that a cause 
and effect relationship has been established between the consumption of alpha-cyclodextrin with 
starch-containing meals and reduction of post-prandial glycaemic responses. The Panel considers that in order to 
obtain the claimed effect, at least 5 g of alpha-cyclodextrin per 50 g of starch should be consumed. The target 
population is adults who wish to reduce their post-prandial glycaemic responses.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a certain 
number of Article 13 health claims would be eligible for further assessment by EFSA in order to be 
able to take a final decision on whether or not to include these claims in the list of permitted health 
claims. This opinion addresses the scientific substantiation of a health claim in relation to 
alpha-cyclodextrin and reduction of post-prandial glycaemic responses. The scientific substantiation is 
based on the information provided by the Member States in the consolidated list of Article 13 health 
claims, references that EFSA has received from Member States or directly from stakeholders, and the 
additional information provided by the competent Authority of the Netherlands for further assessment 
of this claim. 
The food constituent that is the subject of the health claim is alpha-cyclodextrin. The Panel considers 
that alpha-cyclodextrin is sufficiently characterised.  
The claimed effect, which is eligible for further assessment, is reduction of post-prandial glycaemic 
responses. The proposed target population is individuals who wish to reduce their post-prandial 
glycaemic responses. The Panel considers that reduction of post-prandial glycaemic responses (as long 
as post-prandial insulinaemic responses are not disproportionally increased) may be a beneficial 
physiological effect. 
In its earlier opinion the Panel considered one human intervention study and an unpublished project 
report which only contained the description of a study but not the results. In the framework of further 
assessment, 11 additional studies were provided. This evaluation is based on the scientific references 
provided in the present and the previous submission which addressed the effects of alpha-cyclodextrin 
on post-prandial glycaemic responses, and the mechanisms by which alpha-cyclodextrin could exert 
the claimed effect in the target population.   
Six human intervention studies and one systematic review addressed the effects of alpha-cyclodextrin 
on health outcomes other than post-prandial glycaemic responses or of constituents other than alpha-
cylcodextrin. The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claim.  
Two human intervention studies showed an effect of alpha-cyclodextrin added to starch on reduction 
of post-prandial glycaemic responses without disproportionally increasing post-prandial insulinaemic 
responses, while one study in which alpha-cyclodextrin was added to sucrose did not observe such an 
effect. 
With respect to the proposed mechanism, it was stated that due to the structural similarity of 
alpha-cyclodextrin to the helical parts of starch, alpha-cyclodextrin has an inhibitory effect on 
pancreatic amylase, and that alpha-cyclodextrin may also slow gastric emptying. It was also suggested 
that the post-prandial attenuation by alpha-cyclodextrin of the glycaemic and insulinaemic response is 
more pronounced if the meal contains starch rather than sucrose as the glycaemic component. The 
Panel notes that the proposed mechanism (inhibitory effect of alpha-cyclodextrin on pancreatic alpha-
amylase) is in line with the evidence provided from the three intervention studies, i.e. two studies 
conducted with starch showed an effect of alpha-cyclodextrin on post-prandial glycaemic responses, 
whereas the study conducted with sucrose did not show such an effect.  
In weighing the evidence, the Panel took into account that two intervention studies showed a 
significant effect of alpha-cyclodextrin added to starch on post-prandial glycaemic responses without 
disproportionally increasing post-prandial insulinaemic responses, that one study on alpha-
cyclodextrin added to sucrose did not show an effect on post-prandial glycaemic responses, and that 
there is some evidence in support of a plausible mechanism by which alpha-cyclodextrin could exert 
the claimed effect.  
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On the basis of the data provided, the Panel concludes that a cause and effect relationship has been 
established between the consumption of alpha-cyclodextrin with starch-containing meals and 
reduction of post-prandial glycaemic responses. 
The Panel considers that the following wording reflects the scientific evidence: “Consumption of 
alpha-cyclodextrin contributes to the reduction of the blood glucose rise after starch-containing 
meals”. 
The Panel considers that in order to obtain the claimed effect, at least 5 g of alpha-cyclodextrin per 
50 g of starch should be consumed. The target population is adults who wish to reduce their post-
prandial glycaemic responses.  
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006
4
 in which the Panel concluded that the evidence provided was insufficient to establish a 
cause and effect relationship between the consumption of alpha-cyclodextrin and reduction of post-
prandial glycaemic responses (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 
2010), EFSA received additional information from the competent Authority of the Netherlands for 
further assessment of this claim.  
ASSESSMENT 
1. Characterisation of the food/constituent (ID 2926) 
The food that is the subject of the health claim is alpha-cyclodextrin.  
Alpha-cyclodextrin (cyclohexaamylose or cyclomaltohexaose) is a cyclic saccharide comprised of six 
glucose units linked by alpha-1,4 bonds. It is produced by the action of cyclodextrin 
glucosyltransferase on hydrolysed starch syrups. The annular structure of alpha-cyclodextrin provides 
a hydrophobic cavity that allows formation of inclusion complexes with a variety of non-polar organic 
molecules of appropriate size. The hydrophilic nature of the outer surface of the cyclic structure makes 
alpha-cyclodextrin water-soluble. Human salivary and pancreatic amylases cannot hydrolyse 
alpha-cyclodextrin to a significant extent, but alpha-cyclodextrin can be hydrolysed by alpha-amylases 
of bacterial origin in the human intestine. Alpha–cyclodextrin is considered a soluble dietary fibre. 
The Panel considers that the food constituent, alpha-cyclodextrin, which is the subject of the health 
claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health (ID 2926) 
The claimed effect, which is eligible for further assessment, is reduction of post-prandial glycaemic 
responses. The proposed target population is individuals who wish to reduce their post-prandial 
glycaemic responses. 
Postprandial glycaemia is interpreted as the elevation of blood glucose concentrations after 
consumption of a food and/or meal. This function is a normal physiological response which varies in 
magnitude and duration and may be influenced by the chemical and physical nature of the food or 
meal consumed, as well as by individual factors (Venn and Green, 2007). Reducing post-prandial 
blood glucose responses may be beneficial to subjects with impaired glucose tolerance as long as post-
prandial insulinaemic responses are not disproportionally increased. Impaired glucose tolerance is 
common in the general population of adults. 
The Panel considers that reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionally increased) may be a beneficial physiological effect. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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3. Scientific substantiation of the claimed effect (ID 2926) 
In its earlier opinion (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010), the 
Panel considered one human intervention study on the effect of alpha-cyclodextrin on post-prandial 
glycaemic responses (Buckley et al., 2006) and an unpublished project report which only contained the 
description of a study but not the results (Diamantis and Bär, 2002a). Based on the information 
initially provided, the Panel concluded that the evidence was insufficient to establish a cause and 
effect relationship between the consumption of alpha-cyclodextrin and reduction of post-prandial 
glycaemic responses (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010).  
In the framework of further assessment, 11 additional studies (Comerford et al., 2011; Diamantis and 
Bär, 2002b; Gentilcore et al., 2011; Grunberger et al., 2007; Koukiekolo et al., 2001; Li et al., 2009; 
Ochiai et al., 2008; Oudjeriouat et al., 2003; Shimazu et al., 2009; Weyer et al., 2001; Yun et al., 
2009) were provided. Two human intervention studies (Comerford et al., 2011; Grunberger et al., 
2007) investigated the effects of alpha-cyclodextrin on health outcomes (e.g. blood lipids, weight loss, 
and body weight) other than post-prandial glycaemic responses; two human intervention studies 
(Ochiai et al., 2008; Shimazu et al., 2009) addressed the effects of an anti-diabetic medication 
(i.e. acarbose) on adiponectin levels; two papers (Weyer et al., 2001; Yun et al., 2009) described the 
relationship between plasma adiponectin concentrations and insulin sensitivity and insulinaemia in 
obesity and/or type 2 diabetes; and one systematic review (Li et al., 2009) examined the association 
between plasma adiponectin levels and incidence of type 2 diabetes. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim.  
This evaluation is based on the scientific references provided in the present and the previous 
submission which addressed the effects of alpha-cyclodextrin on post-prandial glycaemic responses, 
and the mechanisms by which alpha-cyclodextrin could exert the claimed effect in the target 
population.   
In the study by Buckley et al. (2006), the effects of boiled white rice with 50 g of digestible 
carbohydrates, to which 0, 2, 5 or 10 g of alpha-cyclodextrin were added, on post-prandial glycaemic 
and insulinaemic responses were investigated in 10 healthy subjects (five females), using a 
double-blind, randomised cross-over design. All subjects received the four test meals on a single 
occasion, after an overnight fast, with a wash-out period of two days. Blood glucose and insulin 
concentrations were measured at baseline and over a 2 h period after the ingestion of each meal. 
Repeated measures analysis of variance (RM-ANOVA) followed by pair-wise comparison of the 
means by using a test of least significant differences was used to determine the effects of the 
treatment. The incremental area under the curve (iAUC) for the glucose response was significantly 
lower for the boiled white rice to which 5 g (mean±SEM -20.4±15.4%; p=0.03) or 10 g (mean±SEM -
49.6±9.9%; p=0.001) alpha-cyclodextrin was added compared to the control rice (without alpha-
cyclodextrin). No effect on post-prandial serum insulin concentrations was observed for either dose of 
alpha-cyclodextrin. The Panel notes that this study shows a dose-dependent effect of alpha-
cyclodextrin on reduction of post-prandial glycaemic responses without disproportionally increasing 
post-prandial insulinaemic responses. 
The unpublished study by Diamantis and Bär (2002b) was a single-blind, cross-over study in 
12 healthy males (age 23-24 years and mean weight of 73.3 kg) to determine the effect of 
alpha-cyclodextrin on the glycaemic and insulinaemic response to starch. Subjects consumed either 
100 g white bread (providing 50 g starch) together with 0 or 10 g alpha-cyclodextrin or 25 g alpha-
cyclodextrin alone (alpha-cyclodextrin was dissolved in 250 ml water) in fasting conditions, with a 
wash-out period of at least two days. Blood glucose and serum insulin concentrations were measured 
before and up to 180 min after the consumption of the meal. The glycaemic response of alpha-
cyclodextrin and of white bread with alpha-cyclodextrin was 4.3 % and 43 % relative to that of the 
bread alone (100 %), respectively. The insulinaemic response of white bread with alpha-cyclodextrin 
was 45 % relative to that of the bread alone (100 %). The iAUC for blood glucose concentrations was 
significantly lower after consumption of the starch together with 10 g alpha-cyclodextrin compared to 
alpha-Cyclodextrin and reduction of  
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the control (starch without alpha-cyclodextrin) (-58.63%; mean±SEM: 1543.5±469.6 vs. 3731.2±581.9 
mg/dl/min; p<0.01), as was the iAUC for insulin (-56.48%, mean±SEM: 2559.9±255.2 μU/ml/min vs. 
5883.5±479.0 μU/ml/min; p<0.001). Data were also analysed using a linear mixed model. A 
significant difference between consumption of the starch to which 10 g alpha-cyclodextrin was added 
and consumption of the control starch was found for T15-T90 min for glucose concentrations and for 
T30-T45 min for insulin concentrations. The Panel notes that this study shows an effect of 
alpha-cyclodextrin on reduction of post-prandial glycaemic responses without disproportionally 
increasing post-prandial insulinaemic responses. 
The study by Gentilcore et al. (2011) was a double-blind, randomised cross-over study to investigate 
the effect of alpha-cyclodextrin on the gastric emptying of, and the glycaemic response to, an oral 
sucrose load. Thirteen subjects (median age 70 years, BMI 26.9 kg/m
2
) consumed a drink comprising 
100 g sucrose dissolved in water, or 10 g of alpha-cyclodextrin added to 100 g sucrose before being 
dissolved in water (total volume of the drink 300 ml), with a wash-out period of at least seven days. 
Three subjects did not complete the study. Blood glucose and serum insulin concentrations were 
measured before and up to 300 min after consumption of the drink. Absolute values for blood glucose 
and serum insulin concentrations were analysed using repeated-measures two-way ANOVA followed 
by post hoc analyses of differences between treatments at each time point, corrected for multiple 
comparisons. No statistically significant difference in the iAUC for the glucose and insulin response 
between the control and the alpha-cyclodextrin group was shown. Peak blood glucose (p=0.88) and 
serum insulin (p=0.22) concentrations were not statistically significantly different between the control 
and alpha-cyclodextrin group. A significant treatment x time interaction (p<0.001) for blood glucose 
concentrations was observed. At t=60 min blood glucose was slightly greater (p<0.05) and at t=180 
and 210 min slightly less (p<0.005) after the control drink when compared to alpha-cyclodextrin. The 
Panel notes that this study does not show an effect of alpha-cyclodextrin added to sucrose on reduction 
of post-prandial glycaemic responses. 
With respect to the proposed mechanism, it was stated that due to the structural similarity of 
alpha-cyclodextrin to the helical parts of starch, alpha-cyclodextrin has an inhibitory effect on 
pancreatic amylase, and that alpha-cyclodextrin may also slow gastric emptying. It was also suggested 
that the post-prandial attenuation by alpha-cyclodextrin of the glycaemic and insulinaemic response is 
more pronounced if the meal contains starch rather than sucrose as the glycaemic component.  
One human study (Gentilcore et al., 2011) which investigated the effects of alpha-cyclodextrin on 
gastric emptying, and two in vitro studies (Koukiekolo et al., 2001; Oudjeriouat et al., 2003) on the 
inhibitory effect of alpha-cyclodextrin on pancreatic alpha-amylase and barley amylase were provided 
in support of the proposed mechanisms.  
The human intervention study by Gentilcore et al. (2011), as described above, also measured the 
amounts of the drink remaining in the total, proximal and distal stomach for up to 300 min after 
consumption of the drink, and the 50 % gastric emptying time (T50) was calculated. Gastric emptying 
time, expressed as AUC and T50, was not statistically significantly different between the control and 
the alpha-cyclodextrin group analysed using repeated-measures two-way ANOVA.  
Kinetic studies have been carried out to determine the inhibitory effect of alpha-cyclodextrin on 
porcine pancreatic alpha-amylase using as amylose as the substrate (Koukiekolo et al., 2001). The 
inhibition of amylose hydrolysis by alpha-cyclodextrin was of competitive type with an inhibition 
constant of 7.0 mM. Kinetic studies have also been carried out to determine the inhibitory effect of 
alpha-cyclodextrin on barley alpha-amylase isozymes using DP-4900 amylose as the substrate 
(Oudjeriouat et al., 2003). alpha-Cyclodextrin was shown to be a weak inhibitor of barley alpha-
amylase isozymes, compared to acarbose, a strong inhibitor of pancreatic alpha-amylase. Similar 
results were reported by Rejzek et al. (2011), where alpha-cyclodextrin was shown to have a weak 
inhibitor activity on barley β-amylase when soluble starch was used as the substrate.  
alpha-Cyclodextrin and reduction of  
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Crystallographic analysis showed that three alpha-cyclodextrin molecules bind to the alpha-amylase 
enzyme, two of these in the active site cleft of the amylase and a third quite far from the active site, 
not associated with the substrate-binding cleft (Larson et al., 1994). alpha-Cyclodextrin is considered 
chemically identical to amylose and its cyclic structure resembles the six glycosyl-residue turn in the 
amylose helix. It is quite plausible that the association of alpha-amylose with cyclodextrins reflects the 
binding of helical turns of natural substrate (e.g. amylose). Using crystallographic analyses of porcine 
pancreatic alpha-amylase with alpha-cyclodextrin, a model for the binding of polysaccharides with a 
similar helical character as in natural substrates (i.e. starch and glucagon) was proposed (Larson et al., 
2010). 
The Panel notes that the proposed mechanism (inhibitory effect of alpha-cyclodextrin on pancreatic 
alpha-amylase) is in line with the evidence provided from the three intervention studies, i.e. two 
studies conducted with starch showed an effect of alpha-cyclodextrin on post-prandial glycaemic 
responses, whereas the study conducted with sucrose did not show such an effect.  
In weighing the evidence, the Panel took into account that two intervention studies showed a 
significant effect of alpha-cyclodextrin added to starch on post-prandial glycaemic responses without 
disproportionally increasing post-prandial insulinaemic responses, that one study on alpha-
cyclodextrin added to sucrose did not show an effect on post-prandial glycaemic responses, and that 
there is some evidence in support of a plausible mechanism by which alpha-cyclodextrin could exert 
the claimed effect.  
The Panel concludes that a cause and effect relationship has been established between the 
consumption of alpha-cyclodextrin with starch-containing meals and reduction of post-prandial 
glycaemic responses. 
4. Panel’s comments on the proposed wording (ID 2926) 
The Panel considers that the following wording reflects the scientific evidence: “Consumption of 
alpha-cyclodextrin contributes to the reduction of the blood glucose rise after starch-containing 
meals”. 
5. Conditions and possible restrictions of use (ID 2926) 
The Panel considers that in order to obtain the claimed effect, at least 5 g of alpha-cyclodextrin per 50 
g of starch should be consumed. The target population is adults who wish to reduce their post-prandial 
glycaemic responses.  
CONCLUSIONS  
On the basis of the data presented (initially and for further assessment), the Panel concludes that: 
 The food constituent, alpha-cyclodextrin, that is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect, which is eligible for further assessment, is reduction of post-prandial 
glycaemic responses. The proposed target population is individuals who wish to reduce their 
post-prandial glycaemic responses. Reduction of post-prandial glycaemic responses (as long 
as post-prandial insulinaemic responses are not disproportionally increased) may be a 
beneficial physiological effect. 
 A cause and effect relationship has been established between the consumption of alpha-
cyclodextrin with starch-containing meals and reduction of post-prandial glycaemic responses. 
 The following wording reflects the scientific evidence: “Consumption of alpha-cyclodextrin 
contributes to the reduction of the blood glucose rise after starch-containing meals”. 
alpha-Cyclodextrin and reduction of  
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 In order to bear the claim, at least 5 g of alpha-cyclodextrin per 50 g of starch should be 
consumed. The target population is adults who wish to reduce their post-prandial glycaemic 
responses. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment (No: 
EFSA-Q-2012-00172). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims, references that EFSA has received 
from Member States or directly from stakeholders and the additional information provided by the 
competent Authority of the Netherlands for further assessment of this claim (available on: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation (EC) No 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
alpha-Cyclodextrin and reduction of  
post-prandial glycaemic responses (further assessment)  
 
 
15 EFSA Journal 2012;10(6):2713 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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GLOSSARY AND ABBREVIATIONS 
ANOVA Analysis of variance 
BMI  Body mass index 
DP  Degree of polymerisation 
iAUC  Incremental area under the curve   
RM-ANOVA Repeated measures ANOVA 
 
